^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    disufenton sodium (OKN-007)

    i
    Other names: OKN-007, Oklahoma Nitrone 007
    Company:
    HLB Bio Group
    Drug class:
    Oxygen radical scavenger
    Related drugs:
    8ms
    Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=57, Completed, Oblato, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • disufenton sodium (OKN-007)
    1year
    Sulfatase 2 inhibition sensitizes triple-negative breast cancer cells to paclitaxel through augmentation of extracellular ATP. (PubMed, Cancer Biol Ther)
    The highest incidence and cancer-related mortality rate among women worldwide is due to breast cancer. The co-treatment of chemotherapy and OKN-007 also attenuated cancer-initiating cells. This data implies that the combination of SULF2 inhibitors with chemotherapy augments eATP and decreases cell viability of TNBC greater than chemotherapy alone.
    Journal
    |
    SULF2 (Sulfatase 2)
    |
    paclitaxel • disufenton sodium (OKN-007)
    1year
    Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer. (PubMed, J Pharmacol Exp Ther)
    Our goal was to evaluate the preclinical efficacy and mechanism of action of the anticancer drug Oklahoma Nitrone-007 (OKN-007) alone and in combination with carboplatin and paclitaxel in endometrial cancer. SIGNIFICANCE STATEMENT: Women with advanced and recurrent endometrial cancer have limited therapeutic options. Oklahoma Nitrone-007 (OKN-007), which has minimal toxicity and is currently being evaluated in early-phase clinical trials for the treatment of cancer, is a potential new strategy for the treatment of endometrial cancer.
    Journal • IO biomarker
    |
    mTOR (Mechanistic target of rapamycin kinase) • IFNG (Interferon, gamma) • IDO1 (Indoleamine 2,3-dioxygenase 1) • TGFB1 (Transforming Growth Factor Beta 1) • SULF2 (Sulfatase 2)
    |
    carboplatin • paclitaxel • disufenton sodium (OKN-007)
    over1year
    Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Oblato, Inc. | Trial primary completion date: Dec 2024 --> May 2025
    Trial primary completion date
    |
    disufenton sodium (OKN-007)
    over1year
    Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Oblato, Inc. | Trial completion date: Jan 2025 --> May 2025
    Trial completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • disufenton sodium (OKN-007)
    over1year
    Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Oblato, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Aug 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    disufenton sodium (OKN-007)
    over1year
    OKN-007 is an Effective Anticancer Therapeutic Agent Targeting Inflammatory and Immune Metabolism Pathways in Endometrial Cancer. (PubMed, J Pharmacol Exp Ther)
    Our goal was to evaluate the pre-clinical efficacy and mechanism of action of Oklahoma Nitrone 007 (OKN-007) alone and in combination with carboplatin and paclitaxel in endometrial cancer. Significance Statement Women with advanced and recurrent endometrial cancer have limited therapeutic options. OKN-007, which has minimal toxicity and is currently being evaluated in early-phase clinical trials for the treatment of cancer, is a potential new strategy for the treatment of endometrial cancer.
    Journal • IO biomarker
    |
    IDO1 (Indoleamine 2,3-dioxygenase 1) • TGFB1 (Transforming Growth Factor Beta 1) • SULF2 (Sulfatase 2)
    |
    carboplatin • paclitaxel • disufenton sodium (OKN-007)
    almost2years
    OU-SCC-Oblato-001: OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, University of Oklahoma | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial completion date • Trial primary completion date • Combination therapy
    |
    temozolomide • disufenton sodium (OKN-007)
    almost2years
    Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma (clinicaltrials.gov)
    P2, N=57, Active, not recruiting, Oblato, Inc. | Trial completion date: Mar 2024 --> Jan 2025 | Trial primary completion date: Jul 2023 --> Jun 2024
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase)
    |
    temozolomide • disufenton sodium (OKN-007)
    2years
    Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1, N=16, Recruiting, Oblato, Inc. | Phase classification: P1b --> P1
    Phase classification
    |
    disufenton sodium (OKN-007)
    over2years
    OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=27, Active, not recruiting, University of Oklahoma | Recruiting --> Active, not recruiting | Trial completion date: Jun 2025 --> Nov 2025 | Trial primary completion date: Dec 2023 --> Apr 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
    |
    temozolomide • disufenton sodium (OKN-007)
    over2years
    Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients With Recurrent High-Grade Glioma (clinicaltrials.gov)
    P1b, N=16, Recruiting, Oblato, Inc. | Initiation date: Dec 2022 --> Apr 2023
    Trial initiation date
    |
    disufenton sodium (OKN-007)